New drug combo aims to shrink rare skin cancer before surgery
NCT ID NCT04869137
Summary
This study is testing whether giving two drugs, lenvatinib and pembrolizumab, before surgery can help people with Merkel cell carcinoma, a rare and aggressive skin cancer. The goal is to shrink the tumor as much as possible to make surgery more effective and potentially improve long-term results. The trial is for adults with a tumor that doctors believe can be fully removed with surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MERKEL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.